Charles River Laboratories International, INC. (CRL) — SEC Filings

Overview

Charles River Laboratories International, INC. (CRL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: Charles River Laboratories International, Inc. filed an 8-K to announce the appointment of Mr. George Blankenship as a new independent director to its Board of Directors, effective June 17, 2024. Mr. Blankenship will also join the Audit Committee and the Nominating and Corporate Governance Committee

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 28 neutral. The dominant filing sentiment for Charles River Laboratories International, INC. is neutral.

Filing Type Overview

Charles River Laboratories International, INC. (CRL) has filed 1 ARS, 13 8-K, 6 10-Q, 1 8-K/A, 2 DEF 14A, 4 SC 13G/A, 1 SC 13G, 1 DEFA14A, 1 10-K with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (30)

• ARS Filing — ARS · Mar 31, 2026
• Charles River Labs Appoints George Blankenship to Board — 8-K · Dec 3, 2025
  Charles River Laboratories International, Inc. filed an 8-K to announce the appointment of Mr. George Blankenship as a new independent director to its Board of
• Charles River Labs Appoints George Blankenship to Board — 8-K · Nov 17, 2025
  Charles River Laboratories International, Inc. filed an 8-K to announce the appointment of Mr. George Blankenship as a new independent director to its Board of
• Charles River Labs Sees Q3 Net Income Dip 22% Amid Revenue Stagnation — 10-Q · Nov 5, 2025 Risk: high
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported a mixed financial performance for the three and nine months ended September 27, 2025. Total revenu
• Charles River Labs Files 8-K Amendment on Officer/Director Changes — 8-K/A · Sep 19, 2025 Risk: medium
  Charles River Laboratories International, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on September 19, 2025, related to events occurring on Septem
• Charles River Labs Director Departs; Officer Comp & Reg FD Disclosed — 8-K · Sep 16, 2025 Risk: low
  Charles River Laboratories International, Inc. announced on September 12, 2025, the departure of Director James C. Mullen. The company also reported on compensa
• Charles River Labs Posts Strong Q2 Growth, Net Income Up 12% — 10-Q · Aug 6, 2025 Risk: low
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported a robust financial performance for the second quarter ended June 28, 2025. Total revenue for the three m
• Charles River Labs Adds New Directors, Approves Compensatory Plans — 8-K · May 23, 2025 Risk: low
  Charles River Laboratories International, Inc. announced on May 20, 2025, the election of Dr. David L. Ebersman and Ms. Jennifer L. Smith to its Board of Direct
• Charles River Labs Files Q1 2025 10-Q — 10-Q · May 7, 2025 Risk: low
  Charles River Laboratories International, Inc. filed its 10-Q for the period ending March 29, 2025. The filing details financial performance across its Service
• Charles River Labs Files 8-K: Agreements, Personnel Changes — 8-K · May 7, 2025 Risk: medium
  Charles River Laboratories International, Inc. announced on May 7, 2025, the entry into a material definitive agreement, the departure of directors or certain o
• Charles River Labs Files 2025 Proxy Statement — DEF 14A · Apr 2, 2025 Risk: low
  Charles River Laboratories International, Inc. filed its definitive proxy statement on April 2, 2025, for its annual meeting on May 20, 2025. The filing outline
• Charles River Labs Files 8-K — 8-K · Feb 21, 2025 Risk: low
  Charles River Laboratories International, Inc. filed an 8-K on February 21, 2025, reporting an event on February 20, 2025. The filing is categorized under 'Othe
• Charles River Labs Files 8-K on Financials — 8-K · Feb 19, 2025 Risk: low
  Charles River Laboratories International, Inc. filed an 8-K on February 19, 2025, reporting on its results of operations and financial condition. The filing inc
• Charles River Labs Files 8-K — 8-K · Jan 14, 2025 Risk: low
  Charles River Laboratories International, Inc. filed an 8-K on January 14, 2025, reporting under Regulation FD. The filing details the company's principal execu
• Charles River Labs Files 8-K on Financial Obligation — 8-K · Dec 13, 2024 Risk: medium
  Charles River Laboratories International, Inc. filed an 8-K on December 13, 2024, reporting the creation of a direct financial obligation. The filing does not s
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Charles River Labs Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Charles River Laboratories International, Inc. filed its 10-Q for the period ending September 28, 2024. The filing details financial performance and operational
• SC 13G/A Filing — SC 13G/A · Oct 22, 2024
• Charles River Labs Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
  Charles River Laboratories International, Inc. filed its 10-Q for the period ending June 29, 2024. The filing details financial performance and operational upda
• Charles River Labs Files 8-K on Shareholder Vote Matters — 8-K · May 10, 2024 Risk: low
  Charles River Laboratories International, Inc. filed an 8-K on May 10, 2024, reporting on matters submitted to a vote of security holders on May 8, 2024. The fi
• Charles River Laboratories International, Inc. Files 10-Q for Period Ending March 30, 2024 — 10-Q · May 9, 2024 Risk: low
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Charles River Laboratories International, Inc.
• Charles River Labs Files Additional Proxy Materials — DEFA14A · Apr 24, 2024 Risk: low
  Charles River Laboratories International, Inc. filed a Definitive Additional Materials proxy statement on April 24, 2024. This filing is related to the company'
• Charles River Laboratories Announces 2024 Annual Meeting of Shareholders — DEF 14A · Mar 29, 2024 Risk: low
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) filed a Proxy Statement (DEF 14A) with the SEC on March 29, 2024. Annual Meeting scheduled for May 8, 2024,
• Charles River Labs Files 8-K for Financial Results — 8-K · Feb 14, 2024 Risk: low
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filed an 8-K on February 14, 2024, to report its results of operations and financial condition, along with relate
• Charles River Laboratories International, Inc. Files 2023 Annual Report — 10-K · Feb 14, 2024 Risk: medium
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) filed a Annual Report (10-K) with the SEC on February 14, 2024. Charles River Laboratories International, I
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• CRL Reports Officer/Director Changes, Compensation Arrangements — 8-K · Jan 24, 2024
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) filed an 8-K on January 24, 2024, reporting an event that occurred on January 22, 2024, related to the 'Dep
• BlackRock Amends Charles River Labs Stake, Filing 17th 13G/A — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating its ownership of Common Stock in Charles River Laboratories International Inc. as
• CRL: Officer Changes & Compensation Arrangements Reported — 8-K · Jan 16, 2024
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filed an 8-K on January 16, 2024, reporting an event from January 9, 2024, related to the departure or appointmen

Risk Profile

Risk Assessment: Of CRL's 20 recent filings, 1 were flagged as high-risk, 6 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Charles River Laboratories International, INC.'s most recent 10-Q filing (Nov 5, 2025):

• Revenue: $1,004,852
• Net Income: $54,422
• EPS: $1.10
• Cash Position: $207,097
• Operating Margin: 13.3%

Key Executives

• Board of Directors
• James C. Mullen
• Dr. David L. Ebersman
• Ms. Jennifer L. Smith
• James C. Foster

Industry Context

Charles River Laboratories operates in the life sciences services sector, providing essential products and services to pharmaceutical, biotechnology, and medical device companies. The industry is characterized by high R&D spending, stringent regulatory oversight, and a growing demand for preclinical and clinical research support. Competition is intense, with companies differentiating on service breadth, quality, and specialized expertise.

Top Tags

corporate-governance (5) · 10-Q (4) · compensation (3) · financials (3) · Pharmaceutical Services (2) · Contract Research Organization (2) · Biotechnology (2) · amendment (2) · officer-compensation (2) · regulation-fd (2)

Key Numbers

• Total revenue (Q3 2025): $1,004,852 — Slight decrease from $1,009,763 thousand in Q3 2024
• Net income attributable to CRL (Q3 2025): $54,422 — 21.9% decrease from $69,657 thousand in Q3 2024
• Net income attributable to CRL (YTD 2025): $132,217 — 44.1% decrease from $236,698 thousand in YTD 2024
• Diluted EPS (Q3 2025): $1.10 — Decreased from $1.33 in Q3 2024
• Diluted EPS (YTD 2025): $2.65 — Decreased from $4.37 in YTD 2024
• Operating income (Q3 2025): $133,799 — 14.0% increase from $117,405 thousand in Q3 2024
• Operating income (YTD 2025): $308,602 — 21.9% decrease from $395,034 thousand in YTD 2024
• Cash and cash equivalents (Sept 27, 2025): $207,097 — Increased from $194,606 thousand at Dec 28, 2024
• Net cash provided by operating activities (YTD 2025): $590,126 — Increased from $575,215 thousand in YTD 2024
• Shares outstanding (Oct 25, 2025): 49,215,471 — Total common stock outstanding
• Total Revenue Q2 2025: $1.32B — Increased from $1.21B in Q2 2024, showing 9.1% growth.
• Net Income Q2 2025: $155M — Increased from $138M in Q2 2024, representing a 12.3% rise.
• Service Revenue Q2 2025: $1.15B — Up from $1.05B in Q2 2024, indicating strong demand for services.
• Product Revenue Q2 2025: $170M — Increased from $160M in Q2 2024, reflecting product segment growth.
• Total Assets as of June 28, 2025: $10.5B — Grew from $10.2B at December 28, 2024, demonstrating balance sheet strength.

Related Companies

CRLV · LABD · IQV · LH

Frequently Asked Questions